Innovus Pharmaceuticals 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 14, 2018
Document Information [Line Items]
Entity Registrant Name	INNOVUS PHARMACEUTICALS, INC.
Entity Central Index Key	1,411,879
Trading Symbol	innv
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		216,469,857
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Assets:
Cash	$ 703,012	$ 1,564,859
Accounts receivable, net	356,347	68,259
Prepaid expense and other current assets	1,265,474	363,080
Inventories	2,198,045	1,725,698
Total current assets	4,522,878	3,721,896
Property and equipment, net	206,425	62,454
Deposits	20,881	20,881
Goodwill	952,576	952,576
Intangible assets, net	3,800,674	4,273,099
Total assets	9,503,434	9,030,906
Liabilities:
Accounts payable and accrued expense	2,530,687	2,607,121
Accrued compensation	1,027,068	1,118,293
Deferred revenue and customer deposits	95,372	24,690
Accrued interest payable	24,232	3,648
Derivative liabilities – warrants		58,609
Contingent consideration		28,573
Short-term loan payable	138,048	65,399
Notes payable, net of debt discount of $830,610 and $437,355, respectively	2,340,849	1,239,296
Total current liabilities	6,156,256	5,145,629
Accrued compensation – less current portion	1,227,554	1,531,904
Contingent consideration – less current portion	1,261,455	1,450,430
Total non-current liabilities	2,489,009	2,982,334
Total liabilities	8,645,265	8,127,963
Commitments and contingencies
Stockholders’ equity:
Preferred stock: 7,500,000 shares authorized, at $0.001 par value, no shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively
Common stock: 292,500,000 shares authorized, at $0.001 par value, 208,169,412 and 167,420,605 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	208,169	167,421
Additional paid-in capital	42,350,286	36,375,359
Accumulated deficit	(41,700,286)	(35,639,837)
Total stockholders' equity	858,169	902,943
Total liabilities and stockholders’ equity	$ 9,503,434	$ 9,030,906

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Notes payable, discount, current	$ 830,610	$ 437,355
Preferred stock, shares authorized (in shares)	7,500,000	7,500,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, shares authorized (in shares)	292,500,000	292,500,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares issued (in shares)	208,169,412	167,420,605
Common stock, shares outstanding (in shares)	208,169,412	167,420,605

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net revenue:
Net revenue	$ 7,379,979	$ 2,220,843	$ 19,236,756	$ 6,436,790
Operating expense:
Cost of product sales	1,536,792	480,076	3,739,837	1,329,131
Research and development	59,201	8,736	93,093	26,982
Sales and marketing	5,263,533	1,626,630	14,094,203	4,869,717
General and administrative	2,023,030	1,321,001	5,638,352	4,207,899
Total operating expense	8,882,556	3,436,443	23,565,485	10,433,729
Loss from operations	(1,502,577)	(1,215,600)	(4,328,729)	(3,996,939)
Other income (expense):
Interest expense	(381,663)	(104,276)	(949,533)	(771,885)
Loss on extinguishment of debt	(745,439)	(89,341)	(1,039,711)	(394,169)
Other income (expense), net	290	(4,800)	665	(5,622)
Fair value adjustment for contingent consideration	179,451	69,305	198,250	195,459
Change in fair value of derivative liabilities		16,055		(32,138)
Total other expense, net	(947,361)	(113,057)	(1,790,329)	(1,008,355)
Provision for income taxes				3,200
Net loss	$ (2,449,938)	$ (1,328,657)	$ (6,119,058)	$ (5,008,494)
Net loss per share of common stock – basic and diluted (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.03)
Weighted average number of shares of common stock outstanding – basic and diluted (in shares)	214,527,261	161,587,934	202,290,341	152,325,196
Product [Member]
Net revenue:
Net revenue	$ 6,956,861	$ 2,218,343	$ 18,469,199	$ 6,426,790
License [Member]
Net revenue:
Net revenue	582	2,500	5,737	10,000
Service [Member]
Net revenue:
Net revenue	189,462		345,110
Cooperative Marketing [Member]
Net revenue:
Net revenue	$ 233,074		$ 416,710

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (6,119,058)	$ (5,008,494)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation & amortization	32,093	8,258
(Recovery of) Allowance for doubtful accounts	(179)	5,090
Common stock, restricted stock units and stock options issued to employees, board of directors and consultants for compensation and services	356,058	997,030
Loss on extinguishment of debt	1,039,711	394,169
Change in fair value of contingent consideration	(198,250)	(195,459)
Change in fair value of derivative liabilities		32,138
Amortization of debt discount	898,896	687,598
Amortization of intangible assets	472,425	472,675
Changes in operating assets and liabilities, net of acquisition amounts
Accounts receivable	(287,909)	959
Prepaid expense and other current assets	(764,346)	177,297
Inventories	(472,347)	(40,199)
Accounts payable and accrued expense	(257,647)	506,007
Accrued compensation	(395,575)	433,498
Accrued interest payable	37,560	(6,094)
Deferred revenue and customer deposits	70,682	(11,000)
Net cash used in operating activities	(5,587,887)	(1,546,527)
Cash flows used in investing activities:
Purchase of property and equipment	(176,064)	(10,131)
Contingent consideration payment	(19,298)
Net cash used in investing activities	(195,362)	(10,131)
Cash flows from financing activities:
Payments on short-term loans payable	(245,383)	(7,199)
Proceeds from short-term loans payable	125,000
Proceeds from notes payable	3,722,499	300,000
Payments on notes payable	(1,535,416)	(214,000)
Proceeds from warrant and stock option exercises	2,852,701	4,879
Issuance of common stock for services	2,000
Proceeds from sale of common stock and warrants, net of offering costs		3,307,773
Payments on convertible debentures		(1,222,422)
Prepayment penalty on extinguishment of convertible debentures		(127,247)
Net cash provided by financing activities	4,921,401	2,041,784
Net change in cash	(861,847)	485,126
Cash at beginning of period	1,564,859	829,933
Cash at end of period	703,012	1,315,059
Supplemental disclosures of cash flow information:
Cash paid for income taxes		5,600
Cash paid for interest	4,519	80,344
Supplemental disclosures of non-cash investing and financing activities:
Common stock issued for conversion of convertible debentures and accrued interest	1,288,172	577,835
Reclassification of the fair value of the embedded conversion features from derivative liability to additional paid-in capital upon conversion		203,630
Relative fair value of common stock issued in connection with notes payable recorded as debt discount	693,911	99,386
Fair value of non-forfeitable common stock issued to consultant included in accounts payable and accrued expense		360,000
Offering costs in connection with warrant exercises included in accounts payable and accrued expenses	181,213
Cumulative adjustment to accumulated deficit for the fair value of the warrant derivative liability upon adoption of ASU 2017-11 on January 1, 2018	58,609
Issuance of shares of common stock for vested restricted stock units		92
Fair value of common stock issued for prepayment of future royalties due under the CRI License Agreement included in prepaid expense and other current assets		44,662
Fair value of common stock issued as financing fees in connection with notes payable recorded as debt discount	$ 222,500

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 1 Organization Innovus Pharmaceuticals, Inc., together with its subsidiaries (collectively referred to as “Innovus”, “we”, “our”, “us” or the “Company”) is a Nevada formed, San Diego, California-based emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men’s and women’s health and respiratory diseases. We generate revenue from 31 12 16 Basis of Presentation The condensed consolidated balance sheet as of December 31, 2017, 10 December 31, 2017. September 30, 2018 not December 31, 2018 Change in Accounting Principle On January 1, 2018, No. 2017 11, Earnings Per Share (Topic 260 480 815 no no January 1, 2018. January 1, 2018 $58,609 January 1, 2018. not Liquidity Our operations have been financed primarily through proceeds from convertible debentures and notes payable, sales of our common stock and revenue generated from our products domestically and internationally by our partners. These funds have provided us with the resources to operate our business, sell and support our products, attract and retain key personnel and add new products to our portfolio. We have experienced net losses and negative cash flows from operations each year since our inception. As of September 30, 2018, $41,700,286 $1,633,378. During the nine September 30, 2018, $2.7 5 $3.7 six 4 $1.5 four September 30, 2018 ( 7 As of September 30, 2018, $703,012 $453,675 November 13, 2018 $1,528,293 $387,062 nine September 30, 2018, $5.6 12 June 30, 2016 $1,227,554 may no may not Use of Estimates The preparation of these condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such management estimates include the allowance for doubtful accounts, sales returns and chargebacks, realizability of inventories, valuation of deferred tax assets, goodwill and intangible assets, valuation of contingent acquisition consideration, recoverability of long-lived assets and goodwill and the valuation of equity-based instruments. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions. Fair Value Measurement Our financial instruments are cash, accounts receivable, accounts payable, accrued liabilities, contingent consideration and debt. The recorded values of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The fair value of the contingent acquisition consideration is based upon the present value of expected future payments under the terms of the agreements and is a Level 3 We follow a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 3 three ● Level 1 ● Level 2 1 ● Level 3 Revenue Recognition Our principal activities from which we generate our revenue are product sales. Revenue is measured based on consideration specified in a contract with a customer. A contract with a customer exists when we enter into an enforceable contract with a customer. The contract is based on either the acceptance of standard terms and conditions on the websites for e-commerce customers and via telephone with our third 30 A performance obligation is a promise in a contract to transfer a distinct product to the customer, which for us is transfer of over-the-counter drug and consumer care products to our customers. Performance obligations promised in a contract are identified based on the goods that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract, whereby the transfer of the goods is separately identifiable from other promises in the contract. We have concluded the sale of bottled finished goods and related shipping and handling are accounted for as the single performance obligation. The transaction price of a contract is allocated to each distinct performance obligation and recognized as revenue when or as the customer receives the benefit of the performance obligation. The transaction price is determined based on the consideration to which we will be entitled to receive in exchange for transferring goods to the customer. We issue refunds to e-commerce and print media customers, upon request, within 30 not $213,000 $53,000 September 30, 2018 December 31, 2017, We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer when product is shipped. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of product sales. We enter into exclusive distributor and license agreements that are within the scope of ASC Topic 606. three 1 2 3 no N et Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding and vested but deferred RSUs during the period presented. Diluted net loss per share is computed using the weighted average number of common shares outstanding and vested plus deferred RSUs during the periods plus the effect of dilutive securities outstanding during the periods. For the three nine September 30, 2018 2017, 5 Recent Accounting Pronouncements In June 2018, 2018 07, Compensation – Stock Compensation (Topic 718 718 January 1, 2019, not In January 2017, 2017 04, Intangibles - Goodwill and Other (Topic 350 2 2 December 15, 2019, not In January 2017, 2017 01, Business Combinations (Topic 805 not December 15, 2017, January 1, 2018 In February 2016, No. 2016 02, Leases (Topic 842 606, Revenue from Contracts with Customers no 2016 02 December 15, 2018, not may not 2016 02

Note 2 - Inventory

Note 2 - Inventory	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 2 – INVENTORY Inventories consist of the following: September 30, December 31, 201 8 201 7 Raw materials and supplies $ 317,070 $ 164,469 Work in process 126,883 152,935 Finished goods 1,754,092 1,408,294 Total $ 2,198,045 $ 1,725,698

Note 3 - Intangible Assets and

Note 3 - Intangible Assets and Goodwill	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	NOTE 3 – INTANGIBLE ASSETS AND GOODWILL Amortizable intangible assets consist of the following: September 30, 201 8 Amount Accumulated Amortization Net Amount Useful Lives (years) Patent & Trademarks $ 417,597 $ (150,018 ) $ 267,579 7 – 15 Customer Contracts 611,119 (295,374 ) 315,745 10 Sensum+® License (from CRI) 234,545 (125,056 ) 109,489 10 Vesele® Trademark 25,287 (12,578 ) 12,709 8 Beyond Human® Website and Trade Name 222,062 (101,744 ) 120,318 5 – 10 Novalere Manufacturing Contract 4,681,000 (1,706,615 ) 2,974,385 10 Other Beyond Human® Intangible Assets 4,730 (4,281 ) 449 1 – 3 Total $ 6,196,340 $ (2,395,666 ) $ 3,800,674 December 31, 201 7 Amount Accumulated Amortization Net Amount Useful Lives (years) Patent & Trademarks $ 417,597 $ (124,809 ) $ 292,788 7 – 15 Customer Contracts 611,119 (249,540 ) 361,579 10 Sensum+® License (from CRI) 234,545 (107,464 ) 127,081 10 Vesele® Trademark 25,287 (10,208 ) 15,079 8 Beyond Human® Website and Trade Name 222,062 (72,206 ) 149,856 5 – 10 Novalere Manufacturing Contract 4,681,000 (1,355,540 ) 3,325,460 10 Other Beyond Human® Intangible Assets 4,730 (3,474 ) 1,256 1 – 3 Total $ 6,196,340 $ (1,923,241 ) $ 4,273,099 Amortization expense for the three nine September 30, 2018 2017 $157,475 $157,477 $472,425 $472,675, September 30, 2018 Remainder of 2018 $ 157,475 2019 629,001 2020 628,527 2021 599,598 2022 591,834 2023 558,150 Thereafter 636,089 $ 3,800,674

Note 4 - Notes Payable

Note 4 - Notes Payable	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Long-term Debt [Text Block]	NOTE 4 – NOTES PAYABLE The following table summarizes the outstanding notes payable at September 30, 2018 December 31, 2017: 2018 2017 Notes payable: February 2016 Note Payable $ - $ 54,984 September 2017 5% Note Payable - 165,000 October and December 2017 Notes Payable - 1,066,667 December 2017 5% Note Payable - 390,000 January and March 2018 Notes Payable 411,459 - February and March 2018 5% Notes Payable 720,000 - July 2018 5% Note Payable 550,000 - August 2018 Notes Payable 1,100,000 - September 2018 3.8% Note Payable 390,000 - Total notes payable 3,171,459 1,676,651 Less: Debt discount (830,610 ) (437,355 ) Carrying value 2,340,849 1,239,296 Less: Current portion (2,340,849 ) (1,239,296 ) Notes payable, net of current portion $ - $ - The following table summarizes the future minimum payments as of September 30, 2018 Remainder of 2018 $ 1,004,004 2019 2,167,455 $ 3,171,459 September 2017 5% On September 20, 2017, third $150,000 5% $15,000 $165,000 5% May 20, 2018. In connection with the note, we issued the investor restricted shares of common stock totaling 895,000 $70,169. In April 2018, September 2017 5% 1,474,287 $169,543. $196,080. $169,543 $26,537 $12,050 December 2017 5% On December 13, 2017, third $350,000 5% “December 2017 5% $40,000, 5% $139,750, $133,250 $131,625 June 15, 2018, September 15, 2018 December 15, 2018, On July 23, 2018, December 2017 5% 3,832,695 $402,433. $682,220. $402,433 $279,787 $42,594 October December 2017 On October 17, 2017, October 20, 2017 December 4, 2017, two third $500,000 October 2017 $500,000 December 2017 0% “October December 2017 $200,000 nine $66,667 July 2018 twelve $50,000 December 2018. October December 2017 no 27% October 20% December. On March 1, 2018, October December 2017 2,250,000 October December 2017 $166,667. $384,750. $166,667 $218,083 $37,602 On July 31, 2018, October December 2017 2,380,954 $250,000. $366,667. $250,000 $116,667 $66,753 January March 2018 On January 8, 2018, January 30, 2018, March 1, 2018 March 2, 2018, three third $677,500 January 2018 $550,000 March 2018 0% “January March 2018 $269,375 0% $1,496,875 twelve $68,490 February 2018 January 2019 $56,250 April 2018 March 2019. 22% January March 2018 In connection with the January March 2018 1,282,000 January March 2018 $226,669 January 2018 $187,574 March 2018. 621,317 January 2018 314,737 March 2018 third $67,500 January 2018 $55,000 March 2018 January March 2018 January March 2018 On July 31, 2018, January March 2018 2,857,144 $300,000. $440,000. $300,000 $140,000 $99,638 February March 2018 5% On February 28, 2018 March 28, 2018, two third $650,000 5% “February March 2018 5% $70,000 $720,000 5% October 28, 2018 February 2018 three October 1, 2018, January 1, 2019 April 1, 2019 March 2018. In connection with the February March 2018 5% 1,485,000 February March 2018 5% $93,566 February 2018 $128,695 March 2018. February March 2018 5% July 2018 5% Note Payable On July 19, 2018, third $500,000 5% “July 2018 5% $50,000 $550,000 5% February 19, 2019. In connection with the note, we issued the investor restricted shares of common stock totaling 1,600,000 $176,166. August 201 8 Notes Payable On August 1, 2018, two third $1,000,000 0% “August 2018 $200,000 twelve $100,000 August 2019. August 2018 no 20% In connection with the August 2018 1,000,000 August 2018 $435,322. 638,978 third $100,000 August 2018 August 2018 September 2018 5% On September 12, 2018, third $350,000 5% “September 2018 5% $40,000 $390,000 5% three March 12, 2019, June 12, 2019 September 12, 2019 In connection with the September 2018 5% 1,000,000 September 2018 5% $130,296. Interest Expense We recognized interest expense on notes payable of approximately $14,497 $17,750 $48,275 $64,463 three nine September 30, 2018 2017, three nine September 30, 2018 2017 $364,804 $86,250 $898,896 $687,598,

Note 5 - Stockholders' Equity

Note 5 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 5 – STOCKHOLDERS’ EQUITY Issuances of Common Stock In the first 2018, eleven 18,925,002 $0.15 $2,657,538. 6,741,667 March 21, 2018. March 2017 $181,213 862,917 $0.1875 125% March 2017) March 21, 2023. $136,729 no third 2018, 100,000 $0.15 $13,950. On October 10, 2017, third 2,000,000 January 30, 2018. three March 31, 2018, 166,666 $13,917 During the three nine September 30, 2018, 0 106,486 $0 $10,500 106,486 During the three nine September 30, 2018, 3,600,000 6,367,000 $401,782 $693,911, 4 In connection with the January March 2018 621,317 January 2018 314,737 March 2018 third $67,500 January 2018 $55,000 March 2018 nine September 30, 2018 ( 4 In connection with the August 2018 638,978 March 2018 third $100,000 August 2018 nine September 30, 20018 4 In March 2018, October December 2017 $166,667 2,250,000 4 $384,750 In April 2018, September 2017 5% $169,543 1,474,287 4 $196,080 In July 2018, December 2017 5% $402,433 3,832,695 4 $682,220 In July 2018, January March 2018 $300,000 2,857,144 4 $440,000 In July 2018, October December 2017 $250,000 2,380,954 4 $366,667 2013 We have issued common stock, restricted stock units and stock option awards to employees, non-executive directors and outside consultants under the 2013 “2013 February 2013. 2013 10,000,000 September 30, 2018, no 2013 2014 We have issued common stock, restricted stock units and stock options to employees, non-executive directors and outside consultants under the 2014 “2014 November 2014. 2014 20,000,000 September 30, 2018, 63 2014 2016 We have issued common stock, restricted stock units and stock options to employees, non-executive directors and outside consultants under the 2016 “2016 March 2016. 2016 25,663,199 September 30, 2018, 15,506,569 2016 Stock Options For the nine September 30, 2018 2017, 201 8 201 7 Expected life (in years) 6.23 8.6 Expected volatility 200.6 % 217.0 % Average risk-free interest rate 2.81 % 2.28 % Dividend yield 0 % 0 % Grant date fair value $ 0.15 $ 0.17 The dividend yield of zero no 718. The following table summarizes the number of stock options outstanding and the weighted average exercise price: Options Weighted average exercise price Weighted remaining contractual life (years) Aggregate intrinsic value Outstanding at December 31, 2017 88,000 $ 0.17 8.2 $ 1,590 Granted 282,000 0.15 9.6 280 Exercised - - - - Cancelled - - - - Forfeited - - - - Outstanding at September 30, 2018 370,000 $ 0.15 9.3 $ 1,870 Vested and Expected to Vest at September 30, 2018 370,000 $ 0.15 9.3 $ 1,870 The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding stock options and the quoted price of our common stock at September 30, 2018. three nine September 30, 2018 2017, $4,820 $904 $9,218 $6,310, The weighted average grant date fair value of outstanding stock options for the nine September 30, 2018 $0.15 Restricted Stock Units The following table summarizes the restricted stock unit activity for the nine September 30, 2018: Restricted Stock Units Outstanding at December 31, 2017 13,191,835 Granted 6,805,772 Exchanged (713,541 ) Cancelled (1,536,459 ) Outstanding at September 30, 2018 17,747,607 Vested at September 30, 2018 10,950,904 The vested restricted stock units at September 30, 2018 not not 7 10 may We calculate the fair value of the restricted stock units based upon the quoted market value of the common stock at the date of grant. The grant date fair value of restricted stock units issued during the three nine September 30, 2018 $39,000 $982,292. three nine September 30, 2018 2017, $128,008 $80,125 $325,442 $248,804, September 30, 2018, not $878,289 2.55 Warrants During the year ended December 31, 2014, 2013 135,816 $0.10 December 6, 2018. In January 2015, 250,000 $0.30 January 2015 January 21, 2020. 2015, $0.0896 586,705 December 31, 2015. In connection with the convertible debentures in 2015, $0.30 2020 774,533 September 30, 2018. In connection with the convertible debentures in 2016, $0.40 2021. 4,220,000 September 30, 2018. In connection with the public equity offering in March 2017, 25,666,669 $0.15 25,666,669 $0.15 2022. first 2018, 18,925,002 March 2018. 1,283,333 $0.1875 2022 March 2018 862,917 $0.1875 2023 For the nine September 30, 2018, 201 8 Expected life (in years) 5.0 Expected volatility 183.8 % Average risk-free interest rate 2.69 % Dividend yield 0 % At September 30, 2018, 33,679,973 September 30, 2018 $0.19 3.3 $27,817. Net Loss per Share Restricted stock units that are vested but the issuance and delivery of the shares are deferred until the employee or director resigns are included in the basic and diluted net loss per share calculations. The weighted average shares of common stock outstanding used in the basic and diluted net loss per share calculation for the three nine September 30, 2018 2017 203,576,357 152,250,793 191,530,885 143,192,157, The weighted average restricted stock units vested but issuance of the common stock is deferred until there is a change in control, a specified date in the agreement or the employee or director resigns used in the basic and diluted net loss per share calculation for the three nine September 30, 2018 2017 10,950,904 9,337,141 10,759,456 9,133,039, The total weighted average shares outstanding used in the basic and diluted net loss per share calculation for the three nine September 30, 2018 2017 214,527,261 161,587,934 202,290,341 152,325,196, The following table shows the anti-dilutive shares excluded from the calculation of basic and diluted net loss per common share as of September 30, 2018 2017: As of September 30, 2018 201 7 Gross number of shares excluded: Restricted stock units – unvested 6,796,703 3,437,500 Stock options 370,000 79,000 Warrants 33,679,973 58,583,725 Total 40,846,676 62,100,225 The above table does not 138,859 September 30, 2018 2017,

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 6 In May 2017, 50 No. 207957 November 2017. two one not 90 Litigation James L. Yeager, Ph.D., and Midwest Research Laboratories, LLC v. Innovus Pharmaceuticals, Inc. January 18, 2018, February 26, 2018 ( October 2018, In the ordinary course of business, we may third may, not

Note 7 - Subsequent Events

Note 7 - Subsequent Events	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 7 In October 2018, third $500,000 5% $50,000 $550,000 5% May 1, 2019. 1,600,000 In October 2018, February March 2018 5% $340,036 4,250,445 In November 2018, three third $898,000 0% $202,000 $1,100,000 0% November 6, 2019. 1,200,000 In November 2018, February March 2018 $100,000 1,250,000 We have evaluated subsequent events through the filing date of this Form 10 no

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Nature of Operations, Policy [Policy Text Block	Organization Innovus Pharmaceuticals, Inc., together with its subsidiaries (collectively referred to as “Innovus”, “we”, “our”, “us” or the “Company”) is a Nevada formed, San Diego, California-based emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men’s and women’s health and respiratory diseases. We generate revenue from 31 12 16
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The condensed consolidated balance sheet as of December 31, 2017, 10 December 31, 2017. September 30, 2018 not December 31, 2018
Change in Accounting Principle, Policy [Policy Text Block]	Change in Accounting Principle On January 1, 2018, No. 2017 11, Earnings Per Share (Topic 260 480 815 no no January 1, 2018. January 1, 2018 $58,609 January 1, 2018. not
Liquidity, Policy [Policy Text Block]	Liquidity Our operations have been financed primarily through proceeds from convertible debentures and notes payable, sales of our common stock and revenue generated from our products domestically and internationally by our partners. These funds have provided us with the resources to operate our business, sell and support our products, attract and retain key personnel and add new products to our portfolio. We have experienced net losses and negative cash flows from operations each year since our inception. As of September 30, 2018, $41,700,286 $1,633,378. During the nine September 30, 2018, $2.7 5 $3.7 six 4 $1.5 four September 30, 2018 ( 7 As of September 30, 2018, $703,012 $453,675 November 13, 2018 $1,528,293 $387,062 nine September 30, 2018, $5.6 12 June 30, 2016 $1,227,554 may no may not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of these condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such management estimates include the allowance for doubtful accounts, sales returns and chargebacks, realizability of inventories, valuation of deferred tax assets, goodwill and intangible assets, valuation of contingent acquisition consideration, recoverability of long-lived assets and goodwill and the valuation of equity-based instruments. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurement Our financial instruments are cash, accounts receivable, accounts payable, accrued liabilities, contingent consideration and debt. The recorded values of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The fair value of the contingent acquisition consideration is based upon the present value of expected future payments under the terms of the agreements and is a Level 3 We follow a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 3 three ● Level 1 ● Level 2 1 ● Level 3
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Our principal activities from which we generate our revenue are product sales. Revenue is measured based on consideration specified in a contract with a customer. A contract with a customer exists when we enter into an enforceable contract with a customer. The contract is based on either the acceptance of standard terms and conditions on the websites for e-commerce customers and via telephone with our third 30 A performance obligation is a promise in a contract to transfer a distinct product to the customer, which for us is transfer of over-the-counter drug and consumer care products to our customers. Performance obligations promised in a contract are identified based on the goods that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract, whereby the transfer of the goods is separately identifiable from other promises in the contract. We have concluded the sale of bottled finished goods and related shipping and handling are accounted for as the single performance obligation. The transaction price of a contract is allocated to each distinct performance obligation and recognized as revenue when or as the customer receives the benefit of the performance obligation. The transaction price is determined based on the consideration to which we will be entitled to receive in exchange for transferring goods to the customer. We issue refunds to e-commerce and print media customers, upon request, within 30 not $213,000 $53,000 September 30, 2018 December 31, 2017, We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer when product is shipped. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of product sales. We enter into exclusive distributor and license agreements that are within the scope of ASC Topic 606. three 1 2 3 no
Earnings Per Share, Policy [Policy Text Block]	N et Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding and vested but deferred RSUs during the period presented. Diluted net loss per share is computed using the weighted average number of common shares outstanding and vested plus deferred RSUs during the periods plus the effect of dilutive securities outstanding during the periods. For the three nine September 30, 2018 2017, 5
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In June 2018, 2018 07, Compensation – Stock Compensation (Topic 718 718 January 1, 2019, not In January 2017, 2017 04, Intangibles - Goodwill and Other (Topic 350 2 2 December 15, 2019, not In January 2017, 2017 01, Business Combinations (Topic 805 not December 15, 2017, January 1, 2018 In February 2016, No. 2016 02, Leases (Topic 842 606, Revenue from Contracts with Customers no 2016 02 December 15, 2018, not may not 2016 02

Note 2 - Inventory (Tables)

Note 2 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, 201 8 201 7 Raw materials and supplies $ 317,070 $ 164,469 Work in process 126,883 152,935 Finished goods 1,754,092 1,408,294 Total $ 2,198,045 $ 1,725,698

Note 3 - Intangible Assets an_2

Note 3 - Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	September 30, 201 8 Amount Accumulated Amortization Net Amount Useful Lives (years) Patent & Trademarks $ 417,597 $ (150,018 ) $ 267,579 7 – 15 Customer Contracts 611,119 (295,374 ) 315,745 10 Sensum+® License (from CRI) 234,545 (125,056 ) 109,489 10 Vesele® Trademark 25,287 (12,578 ) 12,709 8 Beyond Human® Website and Trade Name 222,062 (101,744 ) 120,318 5 – 10 Novalere Manufacturing Contract 4,681,000 (1,706,615 ) 2,974,385 10 Other Beyond Human® Intangible Assets 4,730 (4,281 ) 449 1 – 3 Total $ 6,196,340 $ (2,395,666 ) $ 3,800,674 December 31, 201 7 Amount Accumulated Amortization Net Amount Useful Lives (years) Patent & Trademarks $ 417,597 $ (124,809 ) $ 292,788 7 – 15 Customer Contracts 611,119 (249,540 ) 361,579 10 Sensum+® License (from CRI) 234,545 (107,464 ) 127,081 10 Vesele® Trademark 25,287 (10,208 ) 15,079 8 Beyond Human® Website and Trade Name 222,062 (72,206 ) 149,856 5 – 10 Novalere Manufacturing Contract 4,681,000 (1,355,540 ) 3,325,460 10 Other Beyond Human® Intangible Assets 4,730 (3,474 ) 1,256 1 – 3 Total $ 6,196,340 $ (1,923,241 ) $ 4,273,099
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Remainder of 2018 $ 157,475 2019 629,001 2020 628,527 2021 599,598 2022 591,834 2023 558,150 Thereafter 636,089 $ 3,800,674

Note 4 - Notes Payable (Tables)

Note 4 - Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	2018 2017 Notes payable: February 2016 Note Payable $ - $ 54,984 September 2017 5% Note Payable - 165,000 October and December 2017 Notes Payable - 1,066,667 December 2017 5% Note Payable - 390,000 January and March 2018 Notes Payable 411,459 - February and March 2018 5% Notes Payable 720,000 - July 2018 5% Note Payable 550,000 - August 2018 Notes Payable 1,100,000 - September 2018 3.8% Note Payable 390,000 - Total notes payable 3,171,459 1,676,651 Less: Debt discount (830,610 ) (437,355 ) Carrying value 2,340,849 1,239,296 Less: Current portion (2,340,849 ) (1,239,296 ) Notes payable, net of current portion $ - $ -
Schedule of Maturities of Long-term Debt [Table Text Block]	Remainder of 2018 $ 1,004,004 2019 2,167,455 $ 3,171,459

Note 5 - Stockholders' Equity (

Note 5 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	201 8 201 7 Expected life (in years) 6.23 8.6 Expected volatility 200.6 % 217.0 % Average risk-free interest rate 2.81 % 2.28 % Dividend yield 0 % 0 % Grant date fair value $ 0.15 $ 0.17
Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Weighted average exercise price Weighted remaining contractual life (years) Aggregate intrinsic value Outstanding at December 31, 2017 88,000 $ 0.17 8.2 $ 1,590 Granted 282,000 0.15 9.6 280 Exercised - - - - Cancelled - - - - Forfeited - - - - Outstanding at September 30, 2018 370,000 $ 0.15 9.3 $ 1,870 Vested and Expected to Vest at September 30, 2018 370,000 $ 0.15 9.3 $ 1,870
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	Restricted Stock Units Outstanding at December 31, 2017 13,191,835 Granted 6,805,772 Exchanged (713,541 ) Cancelled (1,536,459 ) Outstanding at September 30, 2018 17,747,607 Vested at September 30, 2018 10,950,904
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	201 8 Expected life (in years) 5.0 Expected volatility 183.8 % Average risk-free interest rate 2.69 % Dividend yield 0 %
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of September 30, 2018 201 7 Gross number of shares excluded: Restricted stock units – unvested 6,796,703 3,437,500 Stock options 370,000 79,000 Warrants 33,679,973 58,583,725 Total 40,846,676 62,100,225

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Nov. 13, 2018	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017	Dec. 31, 2016
Retained Earnings (Accumulated Deficit), Ending Balance		$ (41,700,286)			$ (35,639,837)
Working Capital Deficit		1,633,378
Proceeds from Warrant Exercises		2,700,000
Proceeds from Notes Payable, Total		3,722,499	$ 300,000
Cash, Ending Balance		703,012	1,315,059		1,564,859	$ 829,933
Net Cash Provided by (Used in) Operating Activities, Total		(5,587,887)	$ (1,546,527)
Estimated Reserve for Sales Returns and Allowances		$ 213,000			$ 53,000
Wholesalers, Distributors, and Retailers [Member]
Contract with Customer, Payment Period		30 days
Contract with Customer, Refund Period		30 days
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Recorded Liability		$ 1,227,554
Other Current Assets [Member]
Cash Held by Merchant Processors		$ 453,675
Subsequent Event [Member]
Proceeds from Notes Payable, Total	$ 1,500,000
Cash, Ending Balance	1,528,293
Subsequent Event [Member] | Other Current Assets [Member]
Cash Held by Merchant Processors	$ 387,062
Retained Earnings [Member] | Accounting Standards Update 2017-11 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				$ 58,609

Note 2 - Inventory - Inventorie

Note 2 - Inventory - Inventories (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Raw materials and supplies	$ 317,070	$ 164,469
Work in process	126,883	152,935
Finished goods	1,754,092	1,408,294
Total	$ 2,198,045	$ 1,725,698

Note 3 - Intangible Assets an_3

Note 3 - Intangible Assets and Goodwill (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Amortization of Intangible Assets, Total	$ 157,475	$ 157,477	$ 472,425	$ 472,675

Note 3 - Intangible Assets an_4

Note 3 - Intangible Assets and Goodwill - Amortizable Intangible Assets (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Intangible Assets, Amount	$ 6,196,340	$ 6,196,340
Intangible Assets, Accumulated Amortization	(2,395,666)	(1,923,241)
Intangible Assets, Net Amount	3,800,674	4,273,099
Patents and Trademarks [Member]
Intangible Assets, Amount	417,597	417,597
Intangible Assets, Accumulated Amortization	(150,018)	(124,809)
Intangible Assets, Net Amount	$ 267,579	$ 292,788
Patents and Trademarks [Member] | Minimum [Member]
Intangible Assets, Useful Lives (Year)	7 years	7 years
Patents and Trademarks [Member] | Maximum [Member]
Intangible Assets, Useful Lives (Year)	15 years	15 years
Customer Contracts [Member]
Intangible Assets, Amount	$ 611,119	$ 611,119
Intangible Assets, Accumulated Amortization	(295,374)	(249,540)
Intangible Assets, Net Amount	$ 315,745	$ 361,579
Intangible Assets, Useful Lives (Year)	10 years	10 years
Sensum License [Member]
Intangible Assets, Amount	$ 234,545	$ 234,545
Intangible Assets, Accumulated Amortization	(125,056)	(107,464)
Intangible Assets, Net Amount	$ 109,489	$ 127,081
Intangible Assets, Useful Lives (Year)	10 years	10 years
Vesele [Member]
Intangible Assets, Amount	$ 25,287	$ 25,287
Intangible Assets, Accumulated Amortization	(12,578)	(10,208)
Intangible Assets, Net Amount	$ 12,709	$ 15,079
Intangible Assets, Useful Lives (Year)	8 years	8 years
Beyond Human Website and Trade Name [Member]
Intangible Assets, Amount	$ 222,062	$ 222,062
Intangible Assets, Accumulated Amortization	(101,744)	(72,206)
Intangible Assets, Net Amount	$ 120,318	$ 149,856
Beyond Human Website and Trade Name [Member] | Minimum [Member]
Intangible Assets, Useful Lives (Year)	5 years	5 years
Beyond Human Website and Trade Name [Member] | Maximum [Member]
Intangible Assets, Useful Lives (Year)	10 years	10 years
Novalere Mfg. Contract [Member]
Intangible Assets, Amount	$ 4,681,000	$ 4,681,000
Intangible Assets, Accumulated Amortization	(1,706,615)	(1,355,540)
Intangible Assets, Net Amount	$ 2,974,385	$ 3,325,460
Intangible Assets, Useful Lives (Year)	10 years	10 years
Novalere Mfg. Contract [Member] | Minimum [Member]
Intangible Assets, Useful Lives (Year)
Novalere Mfg. Contract [Member] | Maximum [Member]
Intangible Assets, Useful Lives (Year)
Other Beyond Human Intangible Assets [Member]
Intangible Assets, Amount	$ 4,730	$ 4,730
Intangible Assets, Accumulated Amortization	(4,281)	(3,474)
Intangible Assets, Net Amount	$ 449	$ 1,256
Other Beyond Human Intangible Assets [Member] | Minimum [Member]
Intangible Assets, Useful Lives (Year)	1 year	1 year
Other Beyond Human Intangible Assets [Member] | Maximum [Member]
Intangible Assets, Useful Lives (Year)	3 years	3 years

Note 3 - Intangible Assets an_5

Note 3 - Intangible Assets and Goodwill - Expected Future Amortization Expense (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Remainder of 2018	$ 157,475
2,019	629,001
2,020	628,527
2,021	599,598
2,022	591,834
2,023	558,150
Thereafter	636,089
	$ 3,800,674	$ 4,273,099

Note 4 - Notes Payable (Details

Note 4 - Notes Payable (Details Textual)	Dec. 15, 2018USD ($)	Sep. 15, 2018USD ($)	Sep. 12, 2018USD ($)shares	Aug. 01, 2018USD ($)shares	Jul. 31, 2018USD ($)shares	Jul. 23, 2018USD ($)shares	Jul. 19, 2018USD ($)shares	Jun. 15, 2018USD ($)	Mar. 01, 2018USD ($)shares	Dec. 13, 2017USD ($)	Sep. 20, 2017USD ($)shares	Aug. 31, 2018USD ($)shares	Apr. 30, 2018USD ($)shares	Mar. 31, 2018USD ($)shares	Feb. 28, 2018USD ($)	Jan. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)	Oct. 31, 2017USD ($)	Mar. 31, 2018USD ($)shares	Sep. 30, 2018USD ($)shares	Mar. 31, 2018USD ($)shares	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)shares	Sep. 30, 2017USD ($)	May 01, 2018
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares																				3,600,000	166,666		6,367,000
Debt Instrument, Unamortized Discount, Total																	$ 437,355			$ 830,610			$ 830,610
Gain (Loss) on Extinguishment of Debt, Total																				(745,439)		$ (89,341)	(1,039,711)	$ (394,169)
Stock Issued During Period, Value, Restricted Stock Award, Gross																				401,782	$ 13,917		693,911
Interest Expense, Debt, Total																				14,497		17,750	48,275	64,463
Amortization of Debt Discount (Premium)																				$ 364,804		$ 86,250	$ 898,896	$ 687,598
September 2017 Note Payable [Member]
Proceeds from Issuance of Debt											$ 150,000
Debt Instrument, Interest Rate, Stated Percentage											5.00%						5.00%			5.00%			5.00%		5.00%
Debt Instrument, Original Issue Discount											$ 15,000
Debt Instrument, Face Amount											165,000
Debt Instrument, Unamortized Discount, Total											$ 70,169
September 2017 Note Payable [Member] | Fair Value in Excess of the Settled Principal and Interest Balance [Member]
Gain (Loss) on Extinguishment of Debt, Total													$ 26,537
September 2017 Note Payable [Member] | Unamortized Debt Discount [Member]
Gain (Loss) on Extinguishment of Debt, Total													$ 12,050
September 2017 Note Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares													1,474,287
Debt Conversion, Original Debt, Amount													$ 169,543
Debt Conversion, Converted Instrument, Amount													196,080
September 2017 Note Payable [Member] | Unrelated Third Party Investor [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares											895,000
December 2017 Note Payable [Member]
Proceeds from Issuance of Debt										$ 350,000
Debt Instrument, Interest Rate, Stated Percentage										5.00%							5.00%			5.00%			5.00%
Debt Instrument, Original Issue Discount										$ 40,000
Debt Instrument, Periodic Payment, Total		$ 133,250						$ 139,750
Debt Instrument, Number of Payments																	12
Debt Instrument, Periodic Payment, Interest																	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage																	20.00%
December 2017 Note Payable [Member] | Scenario, Forecast [Member]
Debt Instrument, Periodic Payment, Total	$ 131,625
December 2017 Note Payable [Member] | Fair Value in Excess of the Settled Principal and Interest Balance [Member]
Gain (Loss) on Extinguishment of Debt, Total						$ 279,787
December 2017 Note Payable [Member] | Unamortized Debt Discount [Member]
Gain (Loss) on Extinguishment of Debt, Total						$ 42,594
December 2017 Note Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Instrument, Interest Rate, Stated Percentage												5.00%
Debt Conversion, Converted Instrument, Shares Issued | shares						3,832,695						3,832,695
Debt Conversion, Original Debt, Amount						$ 402,433						$ 402,433
Debt Conversion, Converted Instrument, Amount						$ 682,220						$ 682,220
October and December 2017 Notes Payable [Member]
Proceeds from Issuance of Debt																	$ 500,000	$ 500,000
Debt Instrument, Interest Rate, Stated Percentage																	0.00%
Debt Instrument, Original Issue Discount																	$ 200,000
October and December 2017 Notes Payable [Member] | Fair Value in Excess of the Settled Principal and Interest Balance [Member]
Gain (Loss) on Extinguishment of Debt, Total					$ 116,667				$ 218,083
October and December 2017 Notes Payable [Member] | Unamortized Debt Discount [Member]
Gain (Loss) on Extinguishment of Debt, Total					$ 66,753				$ 37,602
October and December 2017 Notes Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares					2,380,954				2,250,000			2,380,954		2,250,000
Debt Conversion, Original Debt, Amount					$ 250,000				$ 166,667			$ 250,000		$ 166,667
Debt Conversion, Converted Instrument, Amount					366,667				$ 384,750			$ 366,667		384,750
October 2017 Notes Payable [Member]
Debt Instrument, Number of Payments																		9
Debt Instrument, Periodic Payment, Interest																		$ 66,667
Debt Instrument, Interest Rate, Effective Percentage																		27.00%
January and March 2018 Notes Payable [Member]
Proceeds from Issuance of Debt														$ 550,000		$ 677,500
Debt Instrument, Interest Rate, Stated Percentage														0.00%					0.00%		0.00%
Debt Instrument, Original Issue Discount														$ 269,375					$ 269,375		$ 269,375
Debt Instrument, Face Amount														$ 1,496,875					$ 1,496,875		$ 1,496,875
Debt Instrument, Number of Payments														12					12		12
Debt Instrument, Interest Rate, Effective Percentage														22.00%					22.00%		22.00%
January and March 2018 Notes Payable [Member] | Fair Value in Excess of the Settled Principal and Interest Balance [Member]
Gain (Loss) on Extinguishment of Debt, Total					140,000
January and March 2018 Notes Payable [Member] | Unamortized Debt Discount [Member]
Gain (Loss) on Extinguishment of Debt, Total					$ 99,638
January and March 2018 Notes Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares					2,857,144							2,857,144
Debt Conversion, Original Debt, Amount					$ 300,000							$ 300,000
Debt Conversion, Converted Instrument, Amount					$ 440,000							$ 440,000
January and March 2018 Notes Payable [Member] | Three Unrelated Third-party Investors [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares																					1,282,000
January and March 2018 Notes Payable [Member] | Third-party Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares														314,737		621,317
Stock Issued During Period, Value, Restricted Stock Award, Gross														$ 55,000		$ 67,500
January 2018 Notes Payable [Member]
Debt Instrument, Unamortized Discount, Total																$ 226,669
Debt Instrument, Periodic Payment, Principal															$ 68,490
January 2018 Notes Payable [Member] | Third-party Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares																621,317
Stock Issued During Period, Value, Restricted Stock Award, Gross																$ 67,500
March 2018 Notes Payable [Member]
Debt Instrument, Unamortized Discount, Total														$ 187,574					$ 187,574		$ 187,574
Debt Instrument, Periodic Payment, Principal													$ 56,250
March 2018 Notes Payable [Member] | Third-party Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares														314,737
Stock Issued During Period, Value, Restricted Stock Award, Gross														$ 55,000
February and March 2018 Notes Payable [Member]
Proceeds from Issuance of Debt																					$ 650,000
Debt Instrument, Interest Rate, Stated Percentage														5.00%			5.00%		5.00%	5.00%	5.00%		5.00%
Debt Instrument, Original Issue Discount														$ 70,000					$ 70,000		$ 70,000
Debt Instrument, Face Amount														720,000					720,000		720,000
Debt Instrument, Unamortized Discount, Total														$ 128,695					$ 128,695		$ 128,695
February and March 2018 Notes Payable [Member] | Two Unrelated Third-party Investors [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares																			1,485,000
Second March 2018 Note Payable [Member]
Debt Instrument, Number of Payments														3					3		3
February 2018 Note Payable [Member]
Debt Instrument, Unamortized Discount, Total															$ 93,566
July 2018 Notes Payable [Member]
Proceeds from Issuance of Debt							$ 500,000
Debt Instrument, Interest Rate, Stated Percentage							5.00%													5.00%			5.00%
Debt Instrument, Original Issue Discount							$ 50,000
Debt Instrument, Face Amount							550,000
Debt Instrument, Unamortized Discount, Total							$ 176,166
July 2018 Notes Payable [Member] | Unrelated Third Party Investor [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares							1,600,000
August 2018 Notes Payable [Member]
Proceeds from Issuance of Debt				$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage				0.00%
Debt Instrument, Original Issue Discount				$ 200,000
Debt Instrument, Unamortized Discount, Total				$ 435,322
Debt Instrument, Number of Payments				12
Debt Instrument, Interest Rate, Effective Percentage				20.00%
Debt Instrument, Periodic Payment, Principal				$ 100,000
August 2018 Notes Payable [Member] | Third-party Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares				638,978										638,978
Stock Issued During Period, Value, Restricted Stock Award, Gross				$ 100,000										$ 100,000
August 2018 Notes Payable [Member] | Two Unrelated Third-party Investors [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares				1,000,000
September 2018 Notes Payable [Member]
Proceeds from Issuance of Debt			$ 350,000
Debt Instrument, Interest Rate, Stated Percentage			5.00%																	3.80%			3.80%
Debt Instrument, Original Issue Discount			$ 40,000
Debt Instrument, Face Amount			390,000
Debt Instrument, Unamortized Discount, Total			$ 130,296
Debt Instrument, Number of Payments			3
September 2018 Notes Payable [Member] | Unrelated Third Party Investor [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares			1,000,000

Note 4 - Notes Payable - Summar

Note 4 - Notes Payable - Summary of Outstanding Notes Payable (Details) - USD ($)	Sep. 30, 2018	Sep. 12, 2018	Aug. 01, 2018	Jul. 19, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 20, 2017
Notes payable	$ 3,171,459					$ 1,676,651
Less: Debt discount	(830,610)					(437,355)
Carrying value	2,340,849					1,239,296
Less: Current portion	(2,340,849)					(1,239,296)
Notes payable, net of current portion
February 2016 Note Payable [Member]
Notes payable						54,984
September 2017 Note Payable [Member]
Notes payable						165,000
Less: Debt discount							$ (70,169)
October and December 2017 Notes Payable [Member]
Notes payable						1,066,667
December 2017 Note Payable [Member]
Notes payable						390,000
January and March 2018 Notes Payable [Member]
Notes payable	411,459
February and March 2018 Notes Payable [Member]
Notes payable	720,000
Less: Debt discount					$ (128,695)
July 2018 Notes Payable [Member]
Notes payable	550,000
Less: Debt discount				$ (176,166)
August 2018 Notes Payable [Member]
Notes payable	1,100,000
Less: Debt discount			$ (435,322)
September 2018 Notes Payable [Member]
Notes payable	$ 390,000
Less: Debt discount		$ (130,296)

Note 4 - Notes Payable - Summ_2

Note 4 - Notes Payable - Summary of Outstanding Notes Payable (Details) (Parentheticals)	Sep. 30, 2018	Sep. 12, 2018	Jul. 19, 2018	May 01, 2018	Mar. 31, 2018	Dec. 31, 2017	Dec. 13, 2017	Sep. 20, 2017
September 2017 Note Payable [Member]
Interest rate	5.00%			5.00%		5.00%		5.00%
December 2017 Note Payable [Member]
Interest rate	5.00%					5.00%	5.00%
February and March 2018 Notes Payable [Member]
Interest rate	5.00%				5.00%	5.00%
July 2018 Notes Payable [Member]
Interest rate	5.00%		5.00%
September 2018 Notes Payable [Member]
Interest rate	3.80%	5.00%

Note 4 - Notes Payable - Future

Note 4 - Notes Payable - Future Minimum Payments for Notes Payable (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Remainder of 2018	$ 1,004,004
2,019	2,167,455
	$ 3,171,459	$ 1,676,651

Note 5 - Stockholders' Equity_2

Note 5 - Stockholders' Equity (Details Textual) - USD ($)	Aug. 01, 2018	Jul. 31, 2018	Jul. 23, 2018	Mar. 01, 2018	Oct. 10, 2017	Aug. 31, 2018	Apr. 30, 2018	Mar. 31, 2018	Jan. 31, 2018	Mar. 31, 2017	Jan. 31, 2015	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2015	May 01, 2018	Dec. 31, 2017	Dec. 13, 2017	Sep. 20, 2017	Mar. 31, 2016	Dec. 31, 2014	Nov. 30, 2014	Feb. 28, 2013
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								1,283,333					1,283,333
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.1875				$ 0.19	$ 0.1875		$ 0.19								$ 0.10
Proceeds from Warrant Exercises															$ 2,700,000
Offering Costs in Connection with Warrant Exercises Included in Accounts Payable and AccruedExpenses															$ 181,213
Percentage of Common Stock Sold in Public Offering										125.00%
Stock Issuable During Period, Shares, Issuable for Services					2,000,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross												3,600,000	166,666		6,367,000
Stock Issued During Period, Value, Restricted Stock Award, Gross												$ 401,782	$ 13,917		$ 693,911
Class of Warrant or Right, Outstanding												33,679,973			33,679,973								135,816
Warrants and Rights Outstanding, Term												3 years 109 days			3 years 109 days
Warrants and Rights Outstanding												$ 27,817			$ 27,817
Weighted Average Number of Shares Outstanding, Basic and Diluted												214,527,261		161,587,934	202,290,341	152,325,196
Acquisition of Novalere [Member]
Number of Consideration Shares												138,859		138,859	138,859	138,859
Minimum [Member]
Settlement of Vested Restricted Stock Units from Date of Issuance, Period															7 years
Maximum [Member]
Settlement of Vested Restricted Stock Units from Date of Issuance, Period															10 years
The 2013 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																									10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant												0			0
The 2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																								20,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant												63			63
The 2016 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																						25,663,199
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant												15,506,569			15,506,569
January and March 2018 Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage								0.00%					0.00%
January and March 2018 Notes Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 300,000				$ 300,000
Debt Conversion, Converted Instrument, Shares Issued		2,857,144				2,857,144
Debt Conversion, Converted Instrument, Amount		$ 440,000				$ 440,000
August 2018 Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage	0.00%
October and December 2017 Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage																			0.00%
October and December 2017 Notes Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Original Debt, Amount		$ 250,000		$ 166,667		$ 250,000		$ 166,667
Debt Conversion, Converted Instrument, Shares Issued		2,380,954		2,250,000		2,380,954		2,250,000
Debt Conversion, Converted Instrument, Amount		$ 366,667		$ 384,750		$ 366,667		$ 384,750
September 2017 Note Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage												5.00%			5.00%			5.00%	5.00%		5.00%
September 2017 Note Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Original Debt, Amount							$ 169,543
Debt Conversion, Converted Instrument, Shares Issued							1,474,287
Debt Conversion, Converted Instrument, Amount							$ 196,080
December 2017 Note Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage												5.00%			5.00%				5.00%	5.00%
December 2017 Note Payable [Member] | Conversion of Debt to Shares of Common Stock [Member]
Debt Conversion, Original Debt, Amount			$ 402,433			$ 402,433
Debt Conversion, Converted Instrument, Shares Issued			3,832,695			3,832,695
Debt Conversion, Converted Instrument, Amount			$ 682,220			$ 682,220
Debt Instrument, Interest Rate, Stated Percentage						5.00%
Restricted Stock [Member]
Stock Issued During Period, Shares, Issued for Services												0			106,486
Restricted Stock [Member] | General and Administrative Expense [Member]
Stock Issued During Period, Value, Issued for Services												$ 0			$ 10,500
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate															0.00%	0.00%
Allocated Share-based Compensation Expense, Total												$ 4,820		$ 9,218	$ 904	$ 6,310
Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance												$ 0.15			$ 0.15
Weighted Average Number of Shares Outstanding, Basic and Diluted												203,576,357		152,250,793	191,530,885	143,192,157
Restricted Stock Units (RSUs) [Member]
Allocated Share-based Compensation Expense, Total												$ 128,008		$ 325,442	$ 80,125	$ 248,804
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value												$ 39,000			$ 982,292
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options												$ 878,289			$ 878,289
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition															2 years 200 days
Weighted Average Number of Shares Outstanding, Basic and Diluted												10,950,904		9,337,141	10,759,456	9,133,039
HCW [Member]
Offering Costs in Connection with Warrant Exercises Included in Accounts Payable and AccruedExpenses													$ 181,213
Class of Warrant or Right, Issued During Period, Fair Value													$ 136,729
Third-party Consultant [Member] | January and March 2018 Notes Payable [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross								314,737	621,317
Stock Issued During Period, Value, Restricted Stock Award, Gross								$ 55,000	$ 67,500
Third-party Consultant [Member] | August 2018 Notes Payable [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	638,978							638,978
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 100,000							$ 100,000
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								18,925,002					18,925,002
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.15					$ 0.15
Proceeds from Warrant Exercises													$ 2,657,538
Class of Warrant or Right, Expired								6,741,667					6,741,667
Warrants in Connection with Public Offering [Member] | HCW [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								862,917					862,917
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.1875					$ 0.1875
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 0.15			$ 0.15
Proceeds from Warrant Exercises												$ 13,950
Class of Warrant or Right, Exercised During Period												100,000
Warrants in Connection with Debenture in 2015 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												774,533			774,533
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 0.30			$ 0.30		$ 0.0896
Class of Warrant or Right, Issued During Period																	586,705
Warrants in Connection with Debenture in 2015 [Member] | Former Executive [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.30
Class of Warrant or Right, Issued During Period											250,000
Warrants in Connection with Debenture in 2016 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												4,220,000			4,220,000
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 0.40			$ 0.40
Series A Warrants in Connection with Public Equity Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										25,666,669
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.15
Series B Warrants in Connection with Public Equity Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								862,917		25,666,669			862,917
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.1875		$ 0.15			$ 0.1875
Class of Warrant or Right, Exercised During Period													18,925,002

Note 5 - Stockholders' Equity -

Note 5 - Stockholders' Equity - Stock Options, Valuation Assumptions (Details) - Stock Options [Member] - $ / shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Expected life (in years) (Year)	6 years 83 days	8 years 219 days
Expected volatility	200.60%	217.00%
Average risk-free interest rate	2.81%	2.28%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Grant date fair value (in dollars per share)	$ 0.15	$ 0.17

Note 5 - Stockholders' Equity_3

Note 5 - Stockholders' Equity - Schedule of Stock Option Activity (Details) - Stock Options [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Outstanding, Options (in shares)	88,000
Outstanding, Weighted average exercise price (in dollars per share)	$ 0.17
Outstanding, Weighted remaining contractual life (Year)	9 years 109 days	8 years 73 days
Outstanding, Aggregate intrinsic value	$ 1,870	$ 1,590
Granted, Options (in shares)	282,000
Granted, Weighted average exercise price (in dollars per share)	$ 0.15
Granted, Weighted remaining contractual life (Year)	9 years 219 days
Granted, Aggregate intrinsic value	$ 280
Exercised, Options (in shares)
Exercised, Weighted average exercise price (in dollars per share)
Cancelled, Options (in shares)
Cancelled, Weighted average exercise price (in dollars per share)
Forfeited, Options (in shares)
Forfeited, Weighted average exercise price (in dollars per share)
Outstanding, Options (in shares)	370,000	88,000
Outstanding, Weighted average exercise price (in dollars per share)	$ 0.15	$ 0.17
Vested and Expected to Vest, Options (in shares)	370,000
Vested and Expected to Vest, Weighted average exercise price (in dollars per share)	$ 0.15
Vested and Expected to Vest, Weighted remaining contractual life (Year)	9 years 109 days
Vested and Expected to Vest, Aggregate intrinsic value	$ 1,870

Note 5 - Stockholders' Equity_4

Note 5 - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2018shares
Outstanding (in shares)	13,191,835
Granted (in shares)	6,805,772
Exchanged (in shares)	(713,541)
Cancelled (in shares)	(1,536,459)
Outstanding (in shares)	17,747,607
Vested (in shares)	10,950,904

Note 5 - Stockholders' Equity_5

Note 5 - Stockholders' Equity - Warrants Valuation Assumptions (Details)	Sep. 30, 2018yr
Measurement Input, Expected Term [Member]
Black-Scholes measurement input for warrants (Year)	5
Measurement Input, Price Volatility [Member]
Black-Scholes measurement input for warrants (Year)	1.838
Measurement Input, Risk Free Interest Rate [Member]
Black-Scholes measurement input for warrants (Year)	0.0269
Measurement Input, Expected Dividend Rate [Member]
Black-Scholes measurement input for warrants (Year)	0

Note 5 - Stockholders' Equity_6

Note 5 - Stockholders' Equity - Schedule of Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities (in shares)	40,846,676	62,100,225
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities (in shares)	6,796,703	3,437,500
Stock Options [Member]
Antidilutive Securities (in shares)	370,000	79,000
Warrant [Member]
Antidilutive Securities (in shares)	33,679,973	58,583,725

Note 6 - Commitments and Cont_2

Note 6 - Commitments and Contingencies (Details Textual)	1 Months Ended
	May 31, 2017
Commercial Agreement, Initial Term	2 years
Commercial Agreement, Automatic Renewal Term	1 year

Note 7 - Subsequent Events (Det

Note 7 - Subsequent Events (Details Textual) - USD ($)	Nov. 13, 2018	Oct. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Debt Instrument, Unamortized Discount, Total			$ 830,610		$ 830,610	$ 437,355
Stock Issued During Period, Shares, Restricted Stock Award, Gross			3,600,000	166,666	6,367,000
Subsequent Event [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	1,200,000	1,600,000
Subsequent Event [Member] | Conversion of Notes Payable to Common Stock [Member]
Debt Conversion, Original Debt, Amount	$ 100,000	$ 340,036
Debt Conversion, Converted Instrument, Shares Issued	1,250,000	4,250,445
October 2018 Notes Payable [Member] | Subsequent Event [Member]
Proceeds from Issuance of Debt		$ 500,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Debt Instrument, Unamortized Discount, Total		$ 50,000
Debt Instrument, Face Amount		$ 550,000
November 2018 Notes Payable [Member] | Subsequent Event [Member]
Proceeds from Issuance of Debt	$ 898,000
Debt Instrument, Interest Rate, Stated Percentage	0.00%
Debt Instrument, Unamortized Discount, Total	$ 202,000
Debt Instrument, Face Amount	$ 1,100,000